Among 2 analysts covering Ameren (NYSE:AEE), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Ameren has $77 highest and $69 lowest target. $76’s average target is -0.77% below currents $76.59 stock price. Ameren had 10 analyst reports since February 11, 2019 according to SRatingsIntel. On Tuesday, February 12 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The rating was maintained by Morgan Stanley with “Hold” on Wednesday, March 13. Morgan Stanley maintained Ameren Corporation (NYSE:AEE) rating on Friday, February 22. Morgan Stanley has “Hold” rating and $73 target. Wells Fargo maintained it with “Outperform” rating and $77 target in Monday, February 11 report. See Ameren Corporation (NYSE:AEE) latest ratings:

25/07/2019 Broker: Argus Research Old Rating: Hold New Rating: Buy Upgrade
21/05/2019 Broker: BidaskScore Rating: Hold Downgrade
15/05/2019 Broker: BidaskScore Rating: Buy Upgrade
24/04/2019 Broker: BidaskScore Rating: Sell Downgrade
02/04/2019 Broker: BidaskScore Rating: Buy Downgrade
13/03/2019 Broker: Morgan Stanley Rating: Hold New Target: $75 Maintain
09/03/2019 Broker: BidaskScore Rating: Buy Upgrade
22/02/2019 Broker: Morgan Stanley Rating: Hold New Target: $73 Maintain
12/02/2019 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $66 New Target: $69 Maintain
11/02/2019 Broker: Wells Fargo Old Rating: Outperform New Rating: Outperform Old Target: $73 New Target: $77 Maintain

Analysts expect Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) to report $-1.84 EPS on August, 13.They anticipate $0.83 EPS change or 82.18% from last quarter’s $-1.01 EPS. After having $-1.41 EPS previously, Biohaven Pharmaceutical Holding Company Ltd.’s analysts see 30.50% EPS growth. The stock increased 3.57% or $1.54 during the last trading session, reaching $44.65. About 631,980 shares traded. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) has risen 115.41% since July 27, 2018 and is uptrending. It has outperformed by 110.98% the S&P500. Some Historical BHVN News: 15/05/2018 - BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD QTRLY SHR LOSS $2.32; 03/04/2018 - Kleo Pharmaceuticals Inc. Appoints Luca Rastelli, PhD as Chief Scientific Officer; 06/03/2018 - Biohaven Pharma 4Q Loss/Shr 75c; 09/05/2018 - Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS); 30/04/2018 - Biohaven Pharmaceutical Holding Closes Above 200-D-MA; 26/03/2018 - BIOHAVEN PHARMACEUTICAL SAYS IN TERMS OF COMPARISON OF RIMEGEPANT WITH ALLERGAN’S UBROGEPANT, THE SAFETY PROFILE THUS FAR FAVOURS RIMEGEPANT - CONF CALL; 19/04/2018 - Biohaven Pharmaceutical Holding Presenting at Conference Apr 23; 15/05/2018 - Biohaven Pharma 1Q Loss $85.5M; 19/04/2018 - Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles; 06/03/2018 - Biohaven Enrolls First Patient in Phase 3 Clinical Trial to Evaluate Rimegepant Zydis ODT in the Acute Treatment of Migraine

The stock increased 0.45% or $0.34 during the last trading session, reaching $76.59. About 1.07 million shares traded. Ameren Corporation (NYSE:AEE) has risen 30.27% since July 27, 2018 and is uptrending. It has outperformed by 25.84% the S&P500. Some Historical AEE News: 13/03/2018 - Vectren draws three suitors in second round; 20/04/2018 - DJ Ameren Corporation, Inst Holders, 1Q 2018 (AEE); 09/05/2018 - AMEREN TARGETS 5-7% COMPOUND ANNUAL EPS GROWTH 2017-2022:SLIDES; 09/04/2018 - Ameren at UBS Chicago Utility Mini Conference Tomorrow; 28/03/2018 - Missouri PSC: PSC Sets Intervention Deadline in Ameren Missouri Electric FAC Charge Cases; 14/03/2018 - Ameren Part of Industry Initiative to Enhance ESG/Sustainability Reporting; 09/05/2018 - AMEREN 1Q OPER REV. $1.59B, EST. $1.55B (2 EST.); 23/05/2018 - AMEREN CORP - ATXI EXPECTS TO INVEST $250 MLN IN MARK TWAIN TRANSMISSION PROJECT; 17/04/2018 - Ameren Corporation First Quarter 2018 Earnings Webcast May 9, 2018; 14/05/2018 - Ameren Illinois Announces Pricing of First Mortgage Bonds Offering due 2028

Investors sentiment increased to 1.11 in Q1 2019. Its up 0.09, from 1.02 in 2018Q4. It is positive, as 29 investors sold Ameren Corporation shares while 151 reduced holdings. 57 funds opened positions while 143 raised stakes. 173.25 million shares or 1.62% less from 176.10 million shares in 2018Q4 were reported. Vaughan Nelson Management Limited Partnership has 0.56% invested in Ameren Corporation (NYSE:AEE) for 569,765 shares. Fisher Asset Management Ltd Liability Corporation holds 5,139 shares or 0% of its portfolio. Northpointe Cap Ltd Llc invested in 55,754 shares or 1.29% of the stock. Tokio Marine Asset Mgmt Limited reported 26,671 shares stake. Northern Tru reported 0.06% in Ameren Corporation (NYSE:AEE). Axa holds 3,957 shares or 0% of its portfolio. 11,028 were reported by Nordea. Mutual Of Omaha Bankshares Wealth Mngmt invested 0.15% of its portfolio in Ameren Corporation (NYSE:AEE). Prudential Public Lc has invested 0.01% in Ameren Corporation (NYSE:AEE). Caisse De Depot Et Placement Du Quebec reported 37,210 shares. Vident Advisory invested 0.18% in Ameren Corporation (NYSE:AEE). Natixis Advsr Lp reported 0.05% stake. 202,142 are owned by Guggenheim Capital Llc. Ameriprise Fin Incorporated has invested 0.16% of its portfolio in Ameren Corporation (NYSE:AEE). Alpha Windward Lc has invested 0.01% in Ameren Corporation (NYSE:AEE).

Ameren Corporation operates as a public utility holding firm in the United States. The company has market cap of $18.81 billion. It operates through four divisions: Ameren Missouri, Ameren Illinois Electric Distribution, Ameren Illinois Natural Gas, and Ameren Transmission. It has a 22.02 P/E ratio. The firm is involved in the rate-regulated electric generation, transmission, and distribution activities; and rate-regulated natural gas transmission and distribution businesses.

More notable recent Ameren Corporation (NYSE:AEE) news were published by: Finance.Yahoo.com which released: “Ameren Corporation (NYSE:AEE) Is Yielding 2.5% - But Is It A Buy? - Yahoo Finance” on July 17, 2019, also Benzinga.com with their article: “Benzinga’s Top Upgrades, Downgrades For July 25, 2019 - Benzinga” published on July 25, 2019, Seekingalpha.com published: “Ameren Missouri requests rate decrease for customers - Seeking Alpha” on July 05, 2019. More interesting news about Ameren Corporation (NYSE:AEE) were released by: Finance.Yahoo.com and their article: “What Kind Of Shareholder Owns Most Ameren Corporation (NYSE:AEE) Stock? - Yahoo Finance” published on May 08, 2019 as well as Prnewswire.com‘s news article titled: “Mark Twain Transmission Project achieves major milestone - PRNewswire” with publication date: July 08, 2019.

More notable recent Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news were published by: Seekingalpha.com which released: “FDA rejects Biohaven’s Nurtec application for ALS - Seeking Alpha” on July 22, 2019, also Prnewswire.com with their article: “Biohaven Enrolls First Patient in Phase 2 Clinical Trial of Rimegepant, Oral CGRP Receptor Antagonist, for Treatment Refractory Trigeminal Neuralgia - PRNewswire” published on July 01, 2019, Prnewswire.com published: “Biohaven Provides Update On Phase 2/3 Alzheimer’s Disease Clinical Trial: Over 400 Patients Enrolled - PRNewswire” on July 22, 2019. More interesting news about Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) were released by: Streetinsider.com and their article: “Biohaven (BHVN) receives CRL from FDA for 505(b)2 application seeking approval for NURTEC for ALS (Earlier) - StreetInsider.com” published on July 22, 2019 as well as Seekingalpha.com‘s news article titled: “Biohaven +2.9% on positive migraine medicine data - Seeking Alpha” with publication date: July 10, 2019.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The company has market cap of $2.30 billion. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. It currently has negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.